漳州片仔癀药业控股股东九龙江集团大规模增持股份，法律意见书详解

关键要点摘要

• 控股股东九龙江集团增持股份：计划于2026年2月1日至2026年7月31日，增持片仔癀A股股份，增持金额区间为人民币3亿元至5亿元。
• 增持方式及资金来源：通过上海证券交易所系统以集中竞价方式，使用自有及专项贷款资金完成增持。
• 增持计划实施情况：截至2026年4月30日，九龙江集团已增持3,171,311股A股，累计增持金额达49,999.76万元，占公司总股本的0.53%，超出计划增持金额下限。
• 增持后的持股比例：九龙江集团合计持有310,693,954股A股，占公司总股本的51.50%。
• 法律合规性：增持行为符合《证券法》《上市公司收购管理办法》《股份变动管理》等相关规范，且免于强制要约收购。
• 信息披露：片仔癀已按规定及时披露相关增持计划、增持实施情况及后续公告义务。
• 主体资格：九龙江集团为国有控股企业，持股结构稳定，无收购管理办法第六条所列禁止情形。

对投资者及股东的重要影响

• 股价潜在影响：控股股东大规模增持，显示对公司前景及价值的高度认可，可能提振市场信心，带来股价积极反应。
• 增持金额已达下限：已完成增持金额下限，表明资金落实到位，后续仍有进一步增持空间，或将继续提升控股权。
• 信息披露合规：增持计划已按要求披露，透明度较高，减少市场不确定性。
• 要约豁免：由于控股股东持股已超30%且持股超过一年，且本次增持不超过2%，依法免于发出要约收购，避免对流通股东造成额外压力。
• 资金来源明确：增持资金包括自有资金及专项贷款，显示财务实力强劲，增强公司资本稳定性。
• 国资背景：九龙江集团由漳州市国资委及福建省财政厅出资，持股结构稳定，有利于公司长期战略规划。

详细解读增持行为

九龙江集团作为漳州片仔癀药业控股股东，计划在2026年2月至7月期间，通过集中竞价方式增持股份，金额区间为3亿元至5亿元。截至2026年4月30日，已增持317万股，金额近5亿元，持股比例升至51.5%。本次增持不仅彰显控股股东对公司未来发展的信心，更进一步巩固其控股地位。

从法律意见书来看，九龙江集团主体资格合规，无重大违法失信记录，亦不涉及收购管理办法第六条禁止情形。增持行为符合《证券法》《收购管理办法》及《股份变动管理》相关规定，且由于持股已超30%、持续一年以上，本次增持不超过2%，依法免于要约收购。

信息披露方面，公司已在上海证券交易所网站及时公告增持计划、资金来源、增持方式及后续进展，保障市场透明度。

股东需关注：增持计划尚未完全结束，后续可能有进一步增持行为，控股股东持股比例有望继续提升，或对公司治理、未来资本运作产生影响。国资控股背景及资金来源可靠，也为公司提供了稳定的支持。

潜在股价影响及投资者关注点

• 控股股东大额增持往往被市场视为利好，有望提升公司估值。
• 后续增持进展需持续关注，有可能进一步推动股价。
• 控股股东资金实力强，显示公司资本稳健。
• 信息披露合规，降低市场波动风险。

免责声明

本资讯仅供投资者参考，不构成任何投资建议。投资者应综合考虑公司基本面、市场环境等因素，独立作出投资决策。法律意见书内容如有更新，以公司公告为准。

English Version

Controlling Shareholder Jiulongjiang Group Significantly Increases Holdings in Zhangzhou Pientzehuang Pharmaceutical – Legal Opinion Detailed

Key Points Summary

• Controlling Shareholder Increases Holdings: Jiulongjiang Group plans to increase its holdings of A shares in Pientzehuang from February 1, 2026 to July 31, 2026, with an increase amount ranging from RMB 300 million to 500 million.
• Acquisition Method & Funding: Purchases are made via centralized bidding on the Shanghai Stock Exchange, using both own funds and dedicated loans.
• Implementation Status: As of April 30, 2026, 3,171,311 A shares have been purchased, totaling RMB 499.9976 million, accounting for 0.53% of total share capital, exceeding the lower limit of the planned amount.
• Post-Acquisition Shareholding: Jiulongjiang Group now holds 310,693,954 A shares, representing 51.50% of the company’s total share capital.
• Compliance: The increase complies with the Securities Law, Takeover Rules, and Share Change Management regulations, and qualifies for exemption from mandatory tender offers.
• Information Disclosure: Pientzehuang has fulfilled timely disclosure obligations regarding the increase plan and its progress.
• Shareholder Qualification: Jiulongjiang Group is a state-owned entity, with stable shareholding and no prohibited circumstances under takeover laws.

Implications for Investors and Shareholders

• Potential Impact on Share Price: Significant increase by controlling shareholder signals strong confidence in company prospects, likely to boost market sentiment and share price.
• Minimum Increase Achieved: The increase has reached the lower bound, showing funds are in place, with room for further increases that could consolidate control.
• Disclosure Transparency: Timely and compliant disclosures reduce market uncertainty.
• Tender Offer Exemption: As controlling stake exceeds 30% for over a year and increase is below 2%, there’s no mandatory tender, avoiding extra pressure on minority shareholders.
• Funding Strength: Backed by own funds and loans, showing strong financial position and capital stability.
• State-Owned Background: Majority owned by Zhangzhou SASAC and Fujian Provincial Department of Finance, providing long-term strategic stability.

Detailed Analysis of the Holdings Increase

Jiulongjiang Group, as the controlling shareholder of Zhangzhou Pientzehuang Pharmaceutical, plans to increase holdings via centralized bidding from February to July 2026, with a planned amount of RMB 300–500 million. As of April 30, 2026, 3.17 million shares have been purchased, with the stake rising to 51.5%. This demonstrates strong confidence in the company’s future and further consolidates its controlling position.

According to the legal opinion, Jiulongjiang Group is fully qualified, with no significant violations or credit issues, and complies with all relevant laws. The increase is exempt from mandatory tender offer due to holding over 30% for more than a year and the increase being below 2%.

Regarding disclosure, Pientzehuang has timely announced the increase plan, funding sources, acquisition methods, and progress, ensuring market transparency.

Shareholders should note: The increase plan is not yet complete, and further increases may occur, possibly boosting controlling shareholder’s stake and impacting governance or future capital operations. State-owned background and clear funding sources offer stable support.

Potential Share Price Movement & Investor Focus

• Significant increase by controlling shareholder is usually seen as a positive, potentially raising valuation.
• Further increase progress should be watched, as it may drive share price higher.
• Strong financial backing indicates capital stability.
• Compliant disclosures lower market risk.

Disclaimer

This information is for reference only and does not constitute investment advice. Investors should consider company fundamentals and market conditions before making decisions. Updates to the legal opinion will be subject to company announcements.

View 片仔癀 Historical chart here